Antihyperglycemic and antidyslipidemic effects of the aqueous extract of Withania adpressa in rats

Abstract

The current study was conducted to evaluate the antihyperglycemic and antidyslipidemic effects of Withania adpressa aqueous extract (WAAE) in 2 experimental animal models. In streptozotocin-induced diabetic rats, daily oral administration of WAAE at a dose of 20 mg/kg for 15 days significantly reduced fasting blood glucose, improved plasma lipid profile, increased hepatic, muscle glycogen content and enhanced liver histological architecture. In another model of tyloxapol-induced hyperlipidemia, a single oral dose of WAAE at 400 mg/kg significantly reduced plasma concentrations of total cholesterol, triglycerides and LDL-c without affecting HDL-c levels. These results highlight the promising therapeutic potential of Withania adpressa in managing metabolic disorders such as diabetes and dyslipidemia.